Motus GI Holdings, Inc. · OTC:MOTS

Motus GI — Investor Presentation (March 2022)

21 slides from Motus GI's investor presentation, March 2022

  1. Slide 1: Breakthrough Solutions for GI Endoscopy

    BREAKTHROUGH SOLUTIONS FOR GI ENDOSCOPY March 2022

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company’s product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, bu

  3. Slide 3: Motus GI Investment Thesis

    Motus GI Patented First Mover Investment Robust Advantage Significant Thesis Clinical Growth Data Opportunities Large Global Experienced Addressable Leadership Market Team 3/7/22 3

  4. Slide 4: Our Mission

    Our Mission Our mission is to provide innovative solutions in GI endoscopy that improve patient outcomes and experiences.

  5. Slide 5: Executive Leadership Team

    Executive Leadership Team Timothy P. Moran I Chief Executive Officer, Board Director Mark Pomeranz I President & Chief Operating Officer Andrew L. Taylor, MBA I Chief Financial Officer Scott C. Aldrich Jr. I VP, Marketing & Strategy Jeff Hutchison I VP, US Sales & Commercial Operations Ravit Ram I V

  6. Slide 6: Large Global Market Opportunity

    Large Global Market Opportunity 54 1 o The unmet need: Insufficient Bowel Prep prior to colonoscopy is a universal issue that can result in delayed and aborted procedures, missed pathology, and more Global Colonoscopy frequent than necessary procedure intervals Procedures Annually o Motus GI’s Pure-

  7. Slide 7: A Closer Look at the US Opportunity

    A Closer Look at the US Opportunity INPATIENT US Market Entry Point ENDOSCOPY ~1.5M 2 ~6.2M ~4.7M 3 Annual Procedures United States OUTPATIENT COLONOSCOPY HIGH MEDICAL NEED See “References” slide at end for footnote details 7

  8. Slide 8: Inpatient Colonoscopy: The Unmet Need

    Inpatient Colonoscopy: The Unmet Need Insufficient bowel prep can lead to unnecessary extended hospitalizations LOWER GI BLEEDS SEVERE ANEMIA ABDOMINAL PAIN ~$2,2985 4 INFECTION Pain per night of Point unrecoverable bed costs per patient (COLONOSCOPY) See “References” slide at end for footnote detai

  9. Slide 9: Our Solution | Novel Technology Ensures Visualization

    Our Solution | Novel Technology Ensures Visualization The Pure-Vu System is indicated to help facilitate the cleaning of a poorly prepared GI tract during an endoscopy procedure. Single Large Five Irrigation Suction Channel Jets 9

  10. Slide 10: FDA Cleared Pure-Vu EVS Disposable Sleeve

    FDA Cleared Pure-Vu EVS Disposable Sleeve Small atraumatic head with large suction port and 5 Jets Single dual lumen tube with flex technology Integrated Easy Load Disposable Handle 2022-03-07 10

  11. Slide 11: The All New Pure-Vu EVS

    The All New Pure-Vu EVS EVS vs Gen2 Disposable Sleeve EVS vs Gen2 Workstation 50% 40% 80% 25% No 35% 20% 25% 1 lighter more increase increase loading lighter reduction reduction less pump (1 tube vs. flexible in suction in Jets fixture in height in length 5) area Gen 2 EVS EVS Gen 2

  12. Slide 12: Our Solution | Novel Technology Ensures Visualization

    Our Solution | Novel Technology Ensures Visualization 32 Granted Patents/27 Pending Worldwide PULSED VORTEX SMART SENSE SMOOTH GLIDE IRRIGATION SUCTION NAVIGATION 12

  13. Slide 13: Pure-Vu System Pricing

    Pure-Vu® System Pricing Pure-Vu® EVS Pure-Vu® EVS Workstation $975 Sleeve Disposable Each Purchase 5/Box Lease -One sleeve fits standard and slim colonoscopes Rental $75,000 / Workstation $1,100 / Sleeve 13

  14. Slide 14: Pure-Vu Consistently Demonstrates Effective Intraprocedural Cleansing

    Pure-Vu Consistently Demonstrates Effective Intraprocedural Cleansing in Patients with IBP In three multi-centered and one single-center studies, patients presenting with an inadequately prepped colon (as determined by the OVER 250 Boston Bowel Preparation Scale) became adequately prepped for colono

  15. Slide 15: The All New Pure-Vu EVS Addressing the Customer Needs

    The All New Pure-Vu EVS Addressing the Customer Needs Wow, I thought this Many of the patients The patient is really There is no room for us patient was clean with dirty colons have dirty, do I have time? to set-up in the ICU difficult anatomy Dirty Scope Loading Improved Navigation Enhanced Suction

  16. Slide 16: Commercial Growth Plan

    Commercial Growth Plan Expanded Commercial Footprint BROADER HOSPITAL DEEPER EXPANSION TO TARGETING PENETRATION AFFILIATED SITES o Academic Medical Centers o General GI Physicians o VA Medical Centers o Rescue Procedures o Community Hospitals o Targeted Hospital o Integrated Delivery Networks Outpat

  17. Slide 17: Growth Opportunity | US High Need Outpatient

    Growth Opportunity | US High Need Outpatient o Elderly o Cancelled or delayed ~23% Present o Diabetic o Missed pathology with Inadequate Prep o Motility/Mobility o Repeat exams represents o Prep tolerance o Short surveillance intervals 4.7M Procedures7 Goal: Gain reimbursement from CMS and Private P

  18. Slide 18: Key Upcoming Catalysts

    Key Upcoming Commercial launch of Pure-Vu EVS Catalysts Organization expansion to drive growth Pure-Vu EVS Upper GI regulatory submission for indication expansion Initiation of new Clinical trial supporting outpatient reimbursement strategy 2022-03-07 18

  19. Slide 19: Follow Our Journey. Share in Our Success.

    Follow Our Journey. Share in Our Success.

  20. Slide 20: Board of Directors

    Board of Directors David Hochman | Chairman Chairman & CEO, Orchestra BioMed; Director of Corbus and Adgero Shervin Korangy | Director President and Chief Executive Officer of Beaver-Visitec International Timothy P. Moran | Chief Executive Officer and Director Seasoned commercial and operating execu

  21. Slide 21: References

    References Slide Reference 6 1. Estimate for calendar year 2021, based on Motus review and analysis of 2019 inpatient market data and 2021 projections for the U.S., as obtained from iData Research Inc. 2. Estimate for calendar year 2021, based on Motus review and analysis of 2019 inpatient market da

Motus GI Holdings — Investor Presentation (March 2022) on 6ix